Home Biosimilar Antibodies Transmembrane Transporters CD markers Brentuximab vedotin
For research use only. Not for use in humans.

Brentuximab vedotin

Synonyms: SGN-035; Adcetris

Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.

Brentuximab vedotin

CAS No. 914088-09-8

Click to purchase products related to Brentuximab vedotin

Quality Control

Batch: D404501 Purity: 98.93% Protein concentration: 9.36mg/ml Endotoxin Level: ＜1EU/mg
98.93

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.
References

Product Details

CAS No. 914088-09-8
DAR 4.2
ADC antiody Brentuximab
ADC cytotoxin MMAE
Formulation 1xPBS
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07178457 NOT_YET_RECRUITING Drug: Brentuximab Vedotin (Bv)|Drug: Placebo Cutaneous T Cell Lymphoma (CTCL); Brentuximab Vedotin Assistance Publique - Hôpitaux de Paris 2025-11-01 PHASE3
NCT05675410 RECRUITING Drug: Brentuximab Vedotin|Drug: Cyclophosphamide|Drug: Dacar Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 National Cancer Institute (NCI) 2023-05-11 PHASE3
NCT04685616 RECRUITING Drug: Doxorubicin|Drug: Bleomycin|Drug: Brentuximab vedotin| Hodgkin Lymphoma University College, London 2022-04-14 PHASE3
NCT07002216 RECRUITING Drug: Brentuximab Vedotin|Drug: Etoposide|Drug: Cyclophospha Hodgkin Lymphoma; Advanced Hodgkin Lymphoma University of Miami 2025-07-15 PHASE2
NCT06563245 RECRUITING Drug: Brentuximab Vedotin for Injection|Drug: Doxorubicin|Dr Classical Hodgkin Lymphoma; Child; Adolescent; Young Adult; Metabolic Response; Survival; Treatment; Brentuximab Vedotin; PET Scan Children's Cancer Group, China 2024-09-25 PHASE2; PHASE3
NCT07275216 RECRUITING Drug: Brentuximab Vedotin|Drug: Dacarbazine|Drug: Gemcitabin Classic Hodgkin Lymphoma City of Hope Medical Center 2026-10-01 PHASE2

(data from https://clinicaltrials.gov, updated on 2025-09-17)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.